0.30
+0.035(+13.46%)
Currency In CAD
Address
15 Prince Arthur Avenue
Toronto, ON M5R 1B2
Canada
Phone
416 922 3460
Website
Sector
Healthcare
Industry
Medical - Devices
Employees
11
First IPO Date
June 18, 2013
| Name | Title | Pay | Year Born |
| Mr. Daniel Marcel Legault J.D., L.L.B. | President, Chief Executive Officer & Secretary | 744,667 | 1958 |
| Mr. Alain Wilson M.B.A., MBA | Chief Financial Officer | 208,581 | N/A |
| Dr. Ana Stegic | Executive Director of Clinical Operations | 257,667 | N/A |
| Mr. Scott Curtis C.F.A., M.Eng | Chief Operating Officer | 296,352 | N/A |
| Dr. David James Vaughan Ph.D. | Chief Development Officer | 406,583 | 1950 |
| Dr. Joseph Stauffer D.O., M.B.A. | Chief Medical Officer | 1.11M | 1966 |
| Ms. Christina Cameron B.B.A. | Vice President of Investor Relations | 0 | N/A |
| Mr. Philip Stern | Vice President of Communications | 0 | N/A |
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.